Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. TNDM
stocks logo

TNDM

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
238.39M
+7.43%
-0.395
-16.96%
250.22M
+2.56%
-0.253
-29.69%
280.12M
-0.89%
-0.082
-81.24%
Estimates Revision
The market is revising Upward the revenue expectations for Tandem Diabetes Care, Inc. (TNDM) for FY2025, with the revenue forecasts being adjusted by 0.48% over the past three months. During the same period, the stock price has changed by -9.88%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.48%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+14.43%
In Past 3 Month
Stock Price
Go Down
down Image
-9.88%
In Past 3 Month
16 Analyst Rating
up Image0
Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 37.79 USD with a low forecast of 18.00 USD and a high forecast of 75.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
6 Hold
1 Sell
Moderate Buy
up Image0
Current: 14.770
sliders
Low
18.00
Averages
37.79
High
75.00
up Image0
Current: 14.770
sliders
Low
18.00
Averages
37.79
High
75.00
Leerink
Outperform
to
NULL
downgrade
$48 -> $38
2025-07-14
Reason
Leerink
Price Target
$48 -> $38
2025-07-14
downgrade
Outperform
to
NULL
Reason
Leerink lowered the firm's price target on Tandem Diabetes to $38 from $48 and keeps an Outperform rating on the shares ahead of quarterly results. The firm is updating estimates to reflect financial statement disclosures and its updated views, and price targets of several names in the space to reflect recent changes in valuation premiums.
Citi
Joanne Wuensch
Neutral -> Sell
downgrade
$24 -> $14
2025-07-09
Reason
Citi
Joanne Wuensch
Price Target
$24 -> $14
2025-07-09
downgrade
Neutral -> Sell
Reason
Citi analyst Joanne Wuensch downgraded Tandem Diabetes to Sell from Neutral with a price target of $14, down from $24. The firm believes the impact of potential competitive bidding on pump manufacturers will be a focus for investors this quarter. Amid mounting competitive pressures, it will be difficult for Tandem shares to rally, the analyst tells investors in a research note. Citi believes the stock will remain under pressure.
Truist
Hold
initiated
$24
2025-06-17
Reason
Truist
Price Target
$24
2025-06-17
initiated
Hold
Reason
Truist initiated coverage of Tandem Diabetes with a Hold rating and $24 price target. New launches should improve Tandem's position in underpenetrated/growth Type 1 and Type 2 diabetes markets and the company can enhance its competitive positioning as Mobi and future designs eventually come to market, but the company still remains over indexed to a slower growth segment that is margin disadvantaged vs. patch, the analyst tells investors in a research note. Truist expects Tandem to grow revenues at 11% for 2024-2028, even as it loses share within growing markets.
Citi
Neutral
maintain
$20 -> $24
2025-05-22
Reason
Citi
Price Target
$20 -> $24
2025-05-22
maintain
Neutral
Reason
Mizuho
Anthony Petrone
Hold
Initiates
$20
2025-04-10
Reason
Mizuho
Anthony Petrone
Price Target
$20
2025-04-10
Initiates
Hold
Reason
Mizuho initiated coverage of Tandem Diabetes with a Neutral rating and $20 price target. The firm's neutral stance reflects both the bullish feedback from its recent physician surveys that call for ongoing insulin pump category share gains from multiple daily injections and the expectations that more conversions will go to competition over the next two years, the analyst tells investors in a research note. Regarding competitive dynamics, Mizuho's sample of doctors sees Tandem losing an incremental 100bps exiting 2025, reflective of higher patient preference for competing patch-pump versus tubed-pump form factors, the firm adds.
Morgan Stanley
Patrick Wood
Buy
to
Hold
Downgrades
$45 → $22
2025-03-05
Reason
Morgan Stanley
Patrick Wood
Price Target
$45 → $22
2025-03-05
Downgrades
Buy
to
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Tandem Diabetes Care Inc (TNDM.O) is -13.59, compared to its 5-year average forward P/E of -22.20. For a more detailed relative valuation and DCF analysis to assess Tandem Diabetes Care Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-22.20
Current PE
-13.59
Overvalued PE
276.42
Undervalued PE
-320.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
196.87
Current EV/EBITDA
28.93
Overvalued EV/EBITDA
480.69
Undervalued EV/EBITDA
-86.95

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
5.30
Current PS
1.00
Overvalued PS
9.09
Undervalued PS
1.51

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders areBuying! The selling amount has increased 1444.53% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 870.81% over the last quarter.
Sold
Bought
Congress Trading
Congress areBuying! The buying amount has increased100%over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 1444.53% over the last month.
Sold
Bought

TNDM News & Events

Events Timeline

(ET)
2025-07-01
10:17:40
Wells says CBP proposal for CGMs expected, insulin pumps inclusion 'a surprise'
select
2025-07-01
08:52:27
Diabetes device maker shares slide after payment scheduling proposal
select
link
2025-06-24 (ET)
2025-06-24
12:14:59
Diabetes stocks rally after RFK comments on HHS campaign
select
Sign Up For More Events
Sign Up For More Events

News

Preview
3.5
07-15Newsfilter
Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity
  • AI in Retina Image Analysis: Artificial Intelligence algorithms are significantly improving the diagnosis of retinal diseases like age-related macular degeneration and diabetic retinopathy, achieving accuracies that can surpass human experts. This technology enables early detection and personalized treatment plans, enhancing patient care and health outcomes.

  • Market Growth and Innovations: The AI-powered retina image analysis market is projected to grow from $2.65 billion in 2023 to approximately $9.4 billion by 2033, driven by advancements in ophthalmology. Companies like Avant Technologies and Ainnova are actively developing AI technologies for early disease detection, with ongoing clinical trials and FDA engagement to validate their innovations.

Preview
4.5
07-10NASDAQ.COM
Stocks Settle Higher on Tech Stock Strength and Lower Bond Yields
  • Stock Market Performance: The S&P 500, Dow Jones, and Nasdaq all closed higher on Wednesday, with the Nasdaq reaching a new all-time high, driven by strong performance in major technology stocks despite President Trump's announcement of new tariffs.

  • Economic Indicators: US mortgage applications rose significantly, while wholesale trade sales unexpectedly fell. Additionally, China's producer prices showed persistent deflationary pressures, and upcoming earnings reports are anticipated to show minimal growth for S&P 500 companies.

Preview
4.5
07-10NASDAQ.COM
Stocks See Support as Investors Await Tariff News
  • Market Performance: The S&P 500, Dow Jones, and Nasdaq indices are all experiencing gains as investors await updates on trade deals and tariffs, while President Trump announced aggressive tariff plans that could impact market sentiment.

  • Economic Indicators: US mortgage applications rose significantly, while China's producer prices fell sharply, indicating ongoing deflationary pressures; the upcoming earnings season is expected to show minimal growth in S&P 500 company earnings.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tandem Diabetes Care Inc (TNDM) stock price today?

The current price of TNDM is 14.77 USD — it has decreased -3.84 % in the last trading day.

arrow icon

What is Tandem Diabetes Care Inc (TNDM)'s business?

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.

arrow icon

What is the price predicton of TNDM Stock?

Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 37.79 USD with a low forecast of 18.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tandem Diabetes Care Inc (TNDM)'s revenue for the last quarter?

Tandem Diabetes Care Inc revenue for the last quarter amounts to 234.42M USD, increased 22.30 % YoY.

arrow icon

What is Tandem Diabetes Care Inc (TNDM)'s earnings per share (EPS) for the last quarter?

Tandem Diabetes Care Inc. EPS for the last quarter amounts to -1.97 USD, increased 203.08 % YoY.

arrow icon

What changes have occurred in the market's expectations for Tandem Diabetes Care Inc (TNDM)'s fundamentals?

The market is revising Upward the revenue expectations for Tandem Diabetes Care, Inc. (TNDM) for FY2025, with the revenue forecasts being adjusted by 0.48% over the past three months. During the same period, the stock price has changed by -9.88%.
arrow icon

How many employees does Tandem Diabetes Care Inc (TNDM). have?

Tandem Diabetes Care Inc (TNDM) has 2650 emplpoyees as of July 20 2025.

arrow icon

What is Tandem Diabetes Care Inc (TNDM) market cap?

Today TNDM has the market capitalization of 983.79M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free